Difficulty: Medium
Average Score: 65%
Practice
All of the following statements regarding cardiac glycoside-induced ventricular tachyarrhythmias are true EXCEPT:
Correct answer
C
Rationale
In this question about cardiac glycoside-induced ventricular tachyarrhythmias, option C is the correct answer. The statement that these arrhythmias occur more frequently in patients with hyperkalemia than in those with hypokalemia is false. The presence of hypokalemia, not hyperkalemia, predisposes individuals to these arrhythmias due to the exacerbation of the cardiac effects of digoxin.
Option A is incorrect because lidocaine is not the drug of choice in treating cardiac glycoside-induced ventricular tachyarrhythmias. Instead, drugs like phenytoin or amiodarone are commonly used.
Option B is incorrect because Digibind (digoxin immune Fab) is the antidote used in cases of digoxin toxicity, not specifically in life-threatening cases of ventricular tachyarrhythmias.
Option D is incorrect because patients with a severely damaged heart are indeed more likely to experience cardiac glycoside-induced ventricular tachyarrhythmias due to the compromised cardiac function.
Educationally, understanding the treatment and management of cardiac glycoside toxicity is crucial for healthcare providers, especially when caring for patients on digoxin therapy. Recognizing the risk factors, signs, and appropriate interventions for cardiac glycoside-induced arrhythmias is essential for patient safety and positive outcomes.
Option A is incorrect because lidocaine is not the drug of choice in treating cardiac glycoside-induced ventricular tachyarrhythmias. Instead, drugs like phenytoin or amiodarone are commonly used.
Option B is incorrect because Digibind (digoxin immune Fab) is the antidote used in cases of digoxin toxicity, not specifically in life-threatening cases of ventricular tachyarrhythmias.
Option D is incorrect because patients with a severely damaged heart are indeed more likely to experience cardiac glycoside-induced ventricular tachyarrhythmias due to the compromised cardiac function.
Educationally, understanding the treatment and management of cardiac glycoside toxicity is crucial for healthcare providers, especially when caring for patients on digoxin therapy. Recognizing the risk factors, signs, and appropriate interventions for cardiac glycoside-induced arrhythmias is essential for patient safety and positive outcomes.